Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Bacillus coagulans

Spore Strain · MTCC 5856 / LactoSpore

Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.

8 human trials, about 60 studies, ~2,000 participants. The written rationale for this grade is still being prepared.

FDA
GRAS
WADA
Not prohibited

Reference only. Not medical advice.

What can go wrong

Generally well tolerated in healthy people and holds GRAS and EFSA QPS safety status, though that status is strain-conditional (confirmed identity, no acquired antibiotic resistance). As with any live-organism supplement, people who are immunocompromised, seriously ill, pregnant, or giving it to a child should consult a qualified healthcare provider before use, since live probiotics carry a rare but documented bacteremia risk in vulnerable patients and pediatric dosing is not self-evident. Long-term effects of routine spore supplementation on overall microbiome diversity are not well characterized, and benefits are strain- and indication-specific rather than general.

Bacillus coagulans is the most-studied spore-forming probiotic, carried by specific strains such as GBI-30 6086 (GanedenBC30), MTCC 5856 (LactoSpore) and Unique IS-2 (MTCC 5260). Because it forms a protective endospore, it survives stomach acid and heat and germinates in the small intestine, which makes it unusually shelf-stable and even bakeable, a delivery advantage traditional probiotics lack. Its best independent evidence is for irritable bowel syndrome, where a 2023 network meta-analysis ranked two of its strains highest for abdominal-pain relief. The widely marketed non-gut claims, muscle recovery and improved protein or amino-acid absorption, come from small trials funded by the strain's manufacturer and are best read as the sponsor's reported findings, not settled fact. The survival advantage is real and separate from any specific proven clinical benefit.

The most-studied spore probiotic. IBS, muscle recovery, and excellent survivability.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • IBS symptom relief, best independent support for abdominal pain (strain-specific)
  • Functional abdominal complaints: pain, bloating, gas (small RCTs)
  • Shelf-stable and heat-tolerant probiotic delivery, including baked foods
  • Manufacturer-reported: post-exercise recovery and amino-acid/protein absorption support (industry-funded)

What people get wrong

  • Often saidAll Bacillus coagulans products are equivalent

    ActuallyThe trial evidence belongs to specific strains (GBI-30 6086, MTCC 5856, Unique IS2). A label reading only 'Bacillus coagulans' with no strain identifier does not automatically inherit that data, and EFSA's safety presumption is likewise strain-conditional (Xie 2023, Nutrients; EFSA QPS 2024).

  • Often said'Lactobacillus sporogenes' is a real Lactobacillus

    ActuallyThere is no valid organism by that name. Lactic-acid bacteria do not form spores, so a spore-forming Lactobacillus is a contradiction; the label is a decades-old misnomer for Bacillus coagulans, corrected in Bergey's Manual back in 1939 (Wikipedia/Bergey's; PMC nomenclature review).

  • Often saidSurviving stomach acid means it works better

    ActuallyExcellent survivability (~97% survive gastric transit in vitro) is a delivery property, not a clinical outcome. Whether germinated cells then produce a specific health benefit is a separate question answered only by endpoint trials, which for this species are strongest for IBS abdominal pain and thinner elsewhere (Maathuis/in vitro TIM-1 work; Xie 2023).

  • Often saidIt's proven to build muscle and boost protein absorption

    ActuallyThose findings come from small trials (Jager 2016, n=29; Stecker/Jager 2020, n=30) supported by the strain's manufacturer, Ganeden Biotech, and are described as improving amino-acid appearance and recovery markers, not as clinical muscle-building proof. They are the sponsor's reported results and await independent replication (Jager 2016 PeerJ; Stecker 2020 Nutr Metab).

Who profits, and who pushes back

  • Xie et al. (2023 network meta-analysis authors)

    Pushes backAuthors, network meta-analysis of 81 IBS probiotic RCTs, Nutrients

    The authors noted that 45 of the included RCTs were funded by commercial companies and that, given inherent heterogeneity, the rankings 'should be interpreted with caution' pending further study.

  • Heyndrickxia coagulans review (2024, Frontiers in Cellular and Infection Microbiology)

    Pushes backPeer-reviewed 2024 species review

    The review characterizes the organism as a 'transient' in the gut whose capacity to reshape the microbiota's ecological balance 'is also limited,' and states that effects vary by individual, dose and frequency, so further work is needed to optimize application.

  • Diversity researchers (spore-probiotic category note)

    Pushes backMicrobiome-diversity perspective

    As with all Bacillus/Heyndrickxia spore probiotics, the long-term effect of routine spore supplementation on microbiome diversity is not well characterized.

  • Sports-nutrition researchers

    Promotes itAcademic

    Documented muscle-recovery and protein-absorption effects; a genuinely interesting non-GI use.

  • Sabinsa / spore brands

    Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.

    Promotes itIngredient suppliers

    Supply LactoSpore and similar strains to many finished products; commercial ingredient interest.

Where the research comes from

Share of published research by country of origin.
PlaceShare of published research
Other36%
USA34%
India30%

Research published from: India, USA, Global.

How we got here

The organism was first isolated in 1915 by American microbiologist B.W. Hammer at the Iowa Agricultural Experiment Station, where it was causing coagulation in canned evaporated milk. In 1935 it was separately re-described in Bergey's Manual as "Lactobacillus sporogenes," a name that is scientifically invalid: lactic-acid bacteria do not form spores, so a spore-forming Lactobacillus cannot exist. It was moved to genus Bacillus in Bergey's seventh edition in 1939, yet the wrong "Lactobacillus sporogenes" label persisted on supplement packaging for decades, an honesty point buyers should know. Later whole-genome work reclassified the species again, to Weizmannia coagulans in 2020 and to Heyndrickxia coagulans in 2023 (honoring microbiologist Marc Heyndrickx). Its endospore survivability drew commercial interest, and named strains accumulated trial evidence in IBS and, unusually for a probiotic, in sports nutrition.

  1. 1915B.W. Hammer isolates the species from spoiled Iowa evaporated milk; named Bacillus coagulans
  2. 1935Re-described in Bergey's Manual as 'Lactobacillus sporogenes,' an invalid name (lactic-acid bacteria do not form spores)
  3. 1939Transferred to genus Bacillus in Bergey's 7th edition; the 'Lactobacillus sporogenes' label nonetheless persists on products for decades
  4. 2009Small IBS RCTs on GBI-30 6086 (Hun; Dolin) report symptom improvement
  5. 2016-2020Ganeden-supported trials report muscle-recovery and protein/amino-acid-absorption effects for GBI-30 6086
  6. 2018Sabinsa-authored pilot (Majeed) reports MTCC 5856 benefit in major depression with IBS
  7. 2020Reclassified as Weizmannia coagulans on genomic grounds
  8. 2023Reclassified again as Heyndrickxia coagulans; network meta-analysis (Xie) ranks B. coagulans strains highest for IBS abdominal pain

At a glance

Type
Spore-forming Bacillus
Best for
IBS, muscle recovery
Brands
LactoSpore, GanedenBC30
Survivability
Excellent

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Bacillus coagulans. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources